Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


O-glycoside

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514027000 Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring 494
514033000 Oxygen of the saccharide radical bonded directly to a polycyclo ring system of three or more carbocyclic rings 172
514035000 Oxygen of the saccharide radical bonded directly to a cyclohexyl ring 143
514026000 Cyclopentanohydrophenanthrene ring system 134
514032000 Oxygen of the saccharide radical bonded to a nonsaccharide hetero ring by acyclic carbon bonding 19
Entries
DocumentTitleDate
20130045934EXTRACTION METHOD USING ULTRA FINE BUBBLES AND LIQUID EXTRACTS OBTAINED THEREOF - The present invention provides an extraction method that either does not use emulsifiers, organic solvents, and the like or can reduce the amount used of emulsifiers, organic solvents, and the like. In addition, the extraction method of present invention can also efficiently extract various components from various materials to be extracted, and can highly maintain potency and the like of the extracted components, in particular if the components are active agents. Furthermore, the extraction method of present invention has excellent safety. The extraction method of present invention is achieved by bringing materials to be extracted into contact with liquid containing ultra fine bubbles for extraction treatment. The ultra fine bubbles utilized during the extraction process preferably have a mode diameter of 500 nm or smaller and a concentration of 1,000,000 or more per 1 ml of liquid.02-21-2013
20130045933ALOE-EMODIN DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have reduced cardiotoxicity. As such, the novel compounds of the invention offer an advantage over currently available drugs. The present invention further relates to methods for preparing the novel Aloe-Emodin Glycoside (AEG) based derivatives, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.02-21-2013
20080287373Topical skin treating kits - A kit comprising a soap-free cleanser and a topical composition which comprises clindamycin or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier, formulations and packages thereof, and methods of using the same to treat various skin disorders.11-20-2008
20130029925Method for Preventing Cancer Metastasis - The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.01-31-2013
20130029924GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF - Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.01-31-2013
20130029923Materials and Methods for Prevention and Treatment of Viral Infections - The subject invention provides a novel and advantageous method for preventing and treating viral infection. Specifically exemplified herein are therapeutic uses of forsythoside A and jacaranone, compounds isolated from traditional Chinese medicinal material such as 01-31-2013
20100144657PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS - The present invention relates to new phenylpiperidine modulators of opioid μ-receptors, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100022463FEED ADDITIVE FOR LAYING HEN AND FEED CONTAINING THE SAME - A feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed characterized by containing a feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed. Namely, a feed additive for laying hens, which is excellent in effect of reinforcing eggshells, shows a particularly remarkable effect of improving eggshell qualities in the second half of the laying period, relieves stress caused by forced molting, cage transfer and so on and can inhibit lowering in the egg-laying rate.01-28-2010
20100016244D-GLUCOPYRANOSE 1-[3,5-BIS (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES, PREPARATION AND USE THEREOF - The invention relates to a D-glucopyranose 1-[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxybenzoate compound defined by formula (I). It applies in particular to the preparation and the use of this compound and of its derivatives for the preparation of medicaments for the treatment and/or prevention of infections with enveloped viruses, and in particular, in humans, the herpes virus, the Aids virus, the flu virus, the hepatitis B virus, the hepatitis C virus, the dengue virus and the ebola virus, and, in animals, the porcine pseudorabies virus, for example.01-21-2010
20080261898COMPOSITION AND METHOD FOR CANCER TREATMENT AND PREVENTION - Compounds, compositions, methods and kits are provided for treating, reducing the risk of, or preventing diseases and/or conditions, such as diseases associated with angiogenesis and/or abnormal cell proliferation, such as cancer. Compounds of the present invention have antiangiogenic and anti-cancer activity with minimum toxic effects on normal cells. Methods for preparing and manufacturing the compounds and pharmaceutical compositions are also provided.10-23-2008
20090186835TREATMENT AND PROPHYLAXIS OF CANCER - A method and composition for the prophylaxis or treatment of humans or animals for cancer using a mixture of sophorolipids.07-23-2009
20090048185Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient - A therapeutic drug for diseases, in which NKT cells or stimulus of NKT cells is involved in deterioration of disease conditions, containing, as an active ingredient, a glycolipid derivative having the formula (I):02-19-2009
20120245109ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE - The present invention relates compounds of the formula (I)09-27-2012
20120245108METHOD OF MODULATING COMPLEMENT FACTOR B (CFB) EXPRESSION IN CELLS - The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression.09-27-2012
20090042812Lipase inhibitors - The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents.02-12-2009
20090306002IRON METABOLISM-IMPROVING AGENT - An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided.12-10-2009
20090306001NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYLNITRONE - Compounds derived from α-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases.12-10-2009
20130072450ANTIOXIDATIVE AND HEPATOPROTECTIVE COMPOSITIONS CONTAINING DIARYLHEPTANOIDS FROM ALNUS JAPONICA - The present invention relates to antioxidative and hepatoprotective compositions, and more particularly to antioxidative and hepatoprotective compositions comprising diarylheptanoid compounds from 03-21-2013
20130072449LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.03-21-2013
20130059803BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.03-07-2013
20110065658METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating hyperuricemia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with an inhibitor of uric acid synthesis. Additionally, pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate or an inhibitor of uric acid synthesis or a supply of carbohydrate and an inhibitor of uric acid synthesis are provided in the instant invention and are provided for use in the inventive methods.03-17-2011
20110065657Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases - Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by α-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.03-17-2011
20090270339Unit Dose Form of Glufosfamide - A lyophilized unit dose form containing about 2 g of glufosfamide is useful in treatment of cancer and other hyper-proliferative diseases.10-29-2009
20090075910DEUTERIUM-ENRICHED FONDAPARINUX - The present application describes deuterium-enriched fondaparinux, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20110028414GLUCOPYRANOSIDE DERIVATIVES - Novel compounds of the formula (I), in which X has the meaning indicated in Patent Claim 02-03-2011
20110028411ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The invention relates to α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods. It also relates to pharmaceutical compositions containing the α-galactoceramide analogs. The methods of manufacture of the invention involve the use of unsaturated intermediate compounds which enable to synthesize α-galactoceramide analogs by a mere metathesis reaction. The α-galactoceramide analogs of the invention are useful as active ingredients of pharmaceutical compositions, particularly in pharmaceutical compositions having anti-cancerous properties.02-03-2011
20110144042Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative - The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.06-16-2011
20110144040Acteoside and acteoside-rich plant extracts for increasing athletic performance in humans - The present invention relates to increasing the athletic performance of humans using acteoside. This may be in the form of a pure compound, or plant extracts containing at least 10% acteoside by weight. Application of this invention provides increased strength, muscle power, endurance, muscle protein content, and reduced fatigue.06-16-2011
20110144039ANTIOXIDATIVE AND HEPATOPROTECTIVE COMPOSITIONS CONTAINING DIARYHEPTANOIDS FROM ALNUS JAPONICA - The present invention relates to antioxidative and hepatoprotective compositions, and more particularly to antioxidative and hepatoprotective compositions comprising diarylheptanoid compounds from 06-16-2011
20090209476PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.08-20-2009
20110130354SULFATED OLIGOSACCHARIDE DERIVATIVES - The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.06-02-2011
20090075911Ester Derivatives of Hyaluronic Acid for the Preparation of Hydrogel Materials by Photocuring - The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.03-19-2009
20110301105COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS - We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.12-08-2011
20110301104Transition state structure of orotate phosphoribosyl transferases and uses thereof - Methods are provided for designing a transition state inhibitor of orotate phosphoribosyltransferase (OPRT) and for inhibiting OPRT.12-08-2011
20090186836METHOD FOR NEUTRALIZING FUNGI USING SOPHOROLIPIDS AND ANTIFUNGAL SOPHOROLIPIDS FOR USE THEREIN - 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octa-decenoate, lactonic and open ring 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, methyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6″-acetate and ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate sophorolipids and uses thereof as antifungal agents.07-23-2009
20100062989OPTIMAL BIOLOGICAL MARKER FOR THE BIOLOGICAL POTENCY OF Emblica Officinalis Gaertn. (AMLA) FRUIT-METHODS AND PRODUCTS THEREOF - Disclosed is the most optimal biomarker for the BIOLOGICAL POTENCY of 03-11-2010
20090281047Compositions And Methods For Immunotherapy - The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy11-12-2009
20090137497ACTIVE INGREDIENT COMBINATIONS OF GLUCOSYL GLYCERIDES AND CREATINE AND/OR CREATININE - Active ingredient combinations of one or more glucosyl glycerides and one or more substances selected from creatine, creatinine, creatine phosphate, creatine sulfate, creatine acetate, creatine ascorbate, and creatine derivatives whose carboxyl group is esterified by a mono- or polyfunctional alcohol, and cosmetic preparations comprising these active ingredient combinations.05-28-2009
20100113371Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.05-06-2010
20090149397TREATMENT OF CANCER WITH COMBINATIONS OF TOPOISOMERASE INHIBITORS AND PARP INHIBITORS - In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase, as well as providing formulations and modes of administering such compositions.06-11-2009
20110201563CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.08-18-2011
20110263518D-Tagatose-Based Compositions and Methods for Preventing and Treating Atherosclerosis, Metabolic Syndrome, and Symptoms Thereof - Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes.10-27-2011
20120190633MONOPHOSPHORYLATED LIPID A DERIVATIVES - The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided.07-26-2012
20120190632ANTI-BACTERIAL INFECTION, INFLAMMATION, AND LEUKEMIA COMPOSITION AND USE THEREOF - A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant 07-26-2012
20120035120GLYCOLIPIDS AS TREATMENT FOR DISEASE - This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.02-09-2012
20110028413Methods of Reducing Methotrexate Nephrotoxicity - The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as methotrexate. The invention provides compositions comprising a substituted cyclodextrin, methotrexate and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the methotrexate.02-03-2011
20120108529PROTEASE INHIBITORS - Compounds useful as protease inhibitors are provided, as are methods of use and preparation of such compounds and compositions containing such compounds. In one embodiment, the compounds are useful for inhibiting HIV protease enzymes, and are therefore useful in slowing the proliferation of HIV.05-03-2012
20120108528NEW THERAPEUTIC APPROACHES FOR TREATING NEUROINFLAMMATORY CONDITIONS - The present invention relates to novel compositions which can be used for the treatment of neuroinflammation, in particular in subjects having a neurodegenerative, autoimmune, infectious, toxic or traumatic disorder. More particularly, the invention relates to combined therapies for treating neuroinflammation. The invention also discloses new methods for treating neuroinflammation pathological conditions in a subject.05-03-2012
20100099632Oligosaccharide Aldonic Acids and Their Topical Use - Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.04-22-2010
20090093418Novel aminoglycosides and uses thereof in the treatment of genetic disorders - A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.04-09-2009
20090258835COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE - The invention provides novel compounds of the Formula (I) that stimulate rates of glucose oxidation in myocardial cells:10-15-2009
20080207535Method of attaching drug compounds to non-reactive polymer surfaces - Polymers are disclosed that are chemically modified to retard bacterial growth. Such modified polymers (e.g. ePTFE and polypropylene) are produced by first creating acid groups on the polymer surface through reactions with an anhydride. The acid groups are then linked to polyethylene glycol (PEG) through esterification or other reactions such as amidation. Preferably, at least two different molecular weight PEG species are employed. The antimicrobial surface is completed by linking antibiotics (e.g. β-lactam antibiotics) to the PEG extensions. One preferred embodiment of such a modified polymer is produced using ePTFE, maleic anhydride (MA), and penicillin (PEN) to yield PEN-PEG-MA-ePTFE, which inhibits gram-positive bacteria. The PEG spacer is critical for PEN function in this context, since PEN-ePTFE is ineffective against bacterial growth. Another preferred embodiment incorporates ampicillin (AMP) and a heterobifunctional PEG, HOOC—(CH08-28-2008
20100249049ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME - The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.09-30-2010
20100249048BETA GLYCOLIPIDS FOR THE TREATMENT OF CALCIFICATION RELATED DEGENERATIVE DISORDERS - The present invention relates to a composition comprising a combination of at least one natural or synthetic β-glycolipid, a mixture of at least two β-glycolipids, a substance which increases the intracellular, extracellular or serum level of a naturally occurring β-glycolipid, or any combination or mixture thereof and at least one phosphate inhibitor or any compound that alters the phosphate binding or transporting into or out of any cell or any membrane or any combination thereof. The combined composition of the invention may be particularly used for treating calcification related degenerative disorders, specifically, vascular and valvular disorders. The invention further provides kits methods and uses thereof for treatment of calcification related disorders.09-30-2010
20110269702POLYACETYLENIC COMPOUNDS FOR PROTECTING AGAINST PANCREATIC ISLET ATROPHY - Pharmaceutical compositions and methods for protecting against atrophy of pancreatic islets in a mammal with metabolic syndrome, prediabetes or diabetes are disclosed. The method comprises administering to the mammal a pharmaceutical composition comprising a compound having a chemical structure of formula (I) in an effective amount and a pharmaceutically acceptable carrier:11-03-2011
20100144655ORGANIC COMPOUNDS - This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.06-10-2010
20110207680Administration of Glufosfamide For The Treatment of Cancer - Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer.08-25-2011
20080287374BREAST CANCER-RESISTANT PROTEIN INHIBITOR - The invention provides a cancer cell useful in screening BCRP-inhibitors, and a BCRP-inhibitor.11-20-2008
20080306013ILLUDIN ANALOGS USEFUL AS ANTITUMOR AGENTS - The present invention provides illudin analogs of the general formula (I):12-11-2008
20100279960BIOTINYLATED HEXADECASACCHARIDES, PREPARATION AND USE THEREOF - The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R11-04-2010
20110028412Herbal enhanced analgesic formulations - The analgesic properties of L-tryptophan and 5-HTP can be safely enhanced with the coadministration of salacin. Salacin can be effectively provided in the form of white willow bark along with other ingredients to further enhance the formulation's analgesic effect. As salacin can cause the loss of vitamin C in humans, the formulation advantageously includes a supplemental amount of vitamin C.02-03-2011
20080207532Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection - Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.08-28-2008
200802075341,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMIC - The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.08-28-2008
20090156512Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient - This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R06-18-2009
201001372316"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds.06-03-2010
20090062216BUTANOL EXTRACT OF BIDENS PILOSA - A method of treating a Th1-mediated disorder includes administering to a subject in need of the treatment an effective amount of a compound of the formula I:03-05-2009
20100144656FEED OR PHARMACEUTICAL COMPOSITION COMPRISING APRAMYCIN OR AN ADEQUATE SALT THEREOF - An apramycin containing supplement feeding stuff for poultry and is used for the prophylaxis and/or the treatment of histomoniasis.06-10-2010
20100144653Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof - Described herein are fatty acid carbohydrate hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.06-10-2010
20110207681USE OF GLUCOSYLGLYCEROL - The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell protective enzymes such as superoxide dismutase. It is thus possible in this manner to protect human skin cells effectively against damaging external influences.08-25-2011
20090298784ISOLATION AND STRUCTURE OF TURBOSTATINS 1-4 - Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures elucidated. The new compounds exhibit significant cancer cell growth inhibition activity against a variety of murine and human cancer cell lines, and as such appear will be useful in the treatment of various forms of neoplastic disease.12-03-2009
20110207682PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF PEPTIC ULCER DISEASES - The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant 08-25-2011
20090253643EQUOL LEVEL REGULATOR - An object of the invention is to provide a medical drug, a food and drink having a role in regulating the concentration of equal in vivo and being capable of taking for a long time with high safety and provide a selective medium for a microorganism having conversion ability to equal and a method of detecting the same. Provided are an equal concentration-raising or reducing agent containing a carbohydrate as an active ingredient; use of a carbohydrate for producing the equal concentration-raising or reducing agent; a method of raising or reducing the concentration of equal by administrating a carbohydrate in an effective dose; a selective medium containing a carbohydrate for a microorganism having conversion ability to equal; and a method of detecting a microorganism having conversion ability to equal by use of the selective medium.10-08-2009
20090137498SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF - There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4′-bromo-2′-[(5-chloro-2-pyridyl)carbamoyl]-6′-β-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2′-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4′-bromo-6′-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof.05-28-2009
20090062215APPLICATION OF D-PSICOSE TO SUPPRESSION OF ABNORMAL CIRCADIAN INCREASE IN BLOOD GLUCOSE LEVEL - A novel use of D-psicose (for suppressing the abnormal intra-day increase of blood glucose level) is provided. A composition containing D-psicose as the active component and for use in suppressing the abnormal intra-day increase of plasma glucose concentration. The composition is a composition in blend with D-psicose and/or a derivative thereof. The composition is in a form selected from sweeteners, seasonings, food additives, food materials, food and drink products, health food and drink products, pharmaceutical products, and feeds and blended with D-psicose, and/or a derivative thereof as the active component, for use in preventing and therapeutically treating diseases requiring the saving of insufficient insulin, the amelioration of insulin sensitivity and the amelioration of hyperglycemia, and/or diseases of which the symptoms can be ameliorated via the suppression of the abnormal intra-day increase of plasma glucose concentration or of which the onset can be prevented via the suppression thereof, such as diabetes mellitus, occult diabetic states, obesity, hyperglycemia, and/or arteriosclerosis. A method for using D-psicose in suppressing the abnormal intra-day increase of plasma glucose concentration, comprising giving D-psicose at given times to suppress the abnormal increase of plasma glucose concentration throughout the day.03-05-2009
20090054353MANNOSYL-1 PHOSPHATES, PREPARATION METHOD AND THERAPEUTIC USE, IN PARTICULAR AGAINST THE CDG-IA SYNDROME - The present invention relates, as medicaments, to the α-D-mannopyranosyl-1 phosphate derivatives of formulae I, II and III:02-26-2009
20090062214Left-Side Glucose Lipid a Analogue - A compound having excellent macrophage activity inhibitory action, which is represented by the general following formula:03-05-2009
20090054352BENZENE DERIVATIVE OR SALT THEREOF - Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli.02-26-2009
20120196813GLYCOSIDE DERIVATIVE AND USES THEREOF - This invention relates to compounds represented by formula (I):08-02-2012
20080261897Formulation Containing a Polyphenol-Containing Composition and Isomaltulose - The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts.10-23-2008
20080261896Testosterone generating and metabolizing enhancer - A testosterone generating and metabolizing enhancer is proposed in the invention, which increases concentrations of testosterone in both seminal vesicle and bloodstream, and may further promote the gene expression of metabolizing testosterone into 5α-reductase of dihydrotestosterone. The testosterone generating and metabolizing enhancer of the invention is characterized in that an effective component thereof may be phenylethanoid glycosides; said phenylethanoid glycosides may comprise at least one of echinacoside and acteoside, or may comprise both echinacoside and acteoside, more preferably. The testosterone generating and metabolizing enhancer of the invention may be applied in medicines, substances for external uses on skin, and foods and beverages for mammals (including humans); as well as an animal feed for mammals.10-23-2008
20080261895Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment - The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention also includes a method of treating at least one central nervous system disorder in a mammal comprising providing to a mammal in need thereof an effective amount of the compounds of the invention.10-23-2008
20080280837Biologically Active Compounds with Anti-Angiogenic Properties - A method for inhibiting angiogenesis in a subject comprising administering to the subject at least one compound of General Formula (I), wherein the ring or any chiral center(s) may be of any configuration; Z is sulphur, oxygen, CH2, C(O), C(O)HN, NH, NRA or hydrogen, in the case where Z is hydrogen then R1 is not present, RA is selected from the set defined for R1 to R5, X and X′ are independently oxygen or nitrogen providing that at least one X of General Formula (I) is nitrogen, X or X′ may also combine independently with one of R1 to R5 to form an azide, R1 to R5 are independently selected from the following definition which includes but is not limited to H or an alkyl, acyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl substituent of 1 to 20 atoms, which is optionally substituted, and can be branched or linear, and R6 and R7 are hydrogen, or may combine to form a carbonyl function.11-13-2008
20110144041Methods for Treating Inflammatory Bowel Disease - A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.06-16-2011
20100152123METHODS AND COMPOSITIONS FOR TREATING DISORDERS CAUSED BY A DEFICIENCY IN A GENE PRODUCT OF A CLN GENE - The present invention provides methods and compositions for treating a disorder associated with a deficiency in a gene product of a CLN gene in a subject (e.g., neuronal ceroid lipofuscinosis (NCL)), comprising administering to the subject an effective amount of a sphingolipid (e.g., galactosylceramide, ceramide, lysophosphatidic acid, sulfatide and any combination thereof), thereby treating the disorder in the subject.06-17-2010
20090253644Radiosensitizer - A radiosensitizer comprising, as an active ingredient, at least one kind of compound selected from the group consisting of a compound represented by the following general formula (10-08-2009
20120142619MEDICINAL CARBOHYDRATES FOR TREATMENT OF RESPIRATORY CONDITIONS - The present invention relates to a method and compounds of Formula (1) and/or (2) or their pharmaceutically acceptable inorganic or organic salt thereof, and their compositions for treating respiratory conditions including post viral/bacterial infections, acute/chronic bronchitis, COPD, cystic fibrosis, and inflammatory conditions. It has been found by the applicants that the compounds of Formula (1) and/or (2) or their pharmaceutically acceptable inorganic or organic salt thereof could speed up the recovery of the viability of damaged respiratory tract cells by restoring sialylglyco-conjugates on their surface.06-07-2012
20100261661COMPOSITIONS AND METHODS FOR INCREASING THE SUPPRESSION OF HUNGER AND REDUCING THE DIGESTIBILITY OF NON-FAT ENERGY SATIETY - The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, over-weight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal.10-14-2010
20120196814(R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4- ]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES - The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.08-02-2012
20110130355USE OF SOPHORICOSIDE IN THE MANUFACTURE OF MEDICAMENTS - The present invention relates to the use of sophoricoside for the prevention and/or the treatment of articular cartilage degeneration or osteoarthritis in post-menopausal women. It is effective and has no side-effects on uterus, breasts and the like as animal-derived estrogen does. It is easy to be extracted and the source thereof is abundant. Therefore, it has a promising marketing prospect.06-02-2011
20110130352THE USE OF THE EFFECTIVE FRACTION OF ALKALOIDS FROM MULBERRY TWIG IN PREPARING HYPOGLYCEMIC AGENTS - The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 06-02-2011
20100261662UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE - The present disclosure is directed to methods and systems for stabilizing an extracellular matrix in a wall of a blood vessel. The method comprises delivering a therapeutic agent into mural thrombus, which covers the wall of the blood vessel. The agent is transported from the mural thrombus into the extracellular matrix of the vessel wall by diffusion. The agent then acts to reduce the enzymatic degradation of protein in the extracellular matrix.10-14-2010
20110059911Antiinfective and Antitumoral Compounds Isolated From Tropical Lianas - The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.03-10-2011
20110059910Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof - The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.03-10-2011
20110059909METHODS FOR TREATING INFLAMMATORY DISORDERS - The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNFα and IL1β.03-10-2011
20110059908COMPOSITIONS COMPRISING LIPOTEICHOIC ACID FOR USE IN TREATING PLEURAL EFFUSION OR PNEUMOTHORAX - The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.03-10-2011
20100197612Composition and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I08-05-2010
20100144654Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane - The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.06-10-2010
20090042811Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds - The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate, or ureido moiety at the C-2 position of the glycerol backbone, and a phosphocholine, phosphonocholine, or glycoside moiety at the C-3 position of the glycerol backbone are described. The synthesis and antiproliferative activity of ether lipids with a naphthol moiety at the C-1 position are also described. These compounds were shown to be potent inhibitors of cancer cell growth. These compounds are useful for killing cancer cells and treating cancer.02-12-2009
20130217639COMPOUND FOR ACTIVATING NATURAL KILLER T CELLS AND PREPARING METHOD THEREOF - The present invention provides a compound selected from compound of formula (I), pharmaceutically acceptable salts of compound of formula (I), and pharmaceutically acceptable prodrugs of compound of formula (I),08-22-2013
20130217640GLYCOSYLATED ACETAMINOPHEN PRO-DRUG - The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of acetaminophen derivatives.08-22-2013
20090075909Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.03-19-2009
20110130353HIGHLY PURIFIED ANTIENDOTOXIN COMPOUND - The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.06-02-2011
20100197613METHODS FOR INHIBITION OF NKT CELLS - Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.08-05-2010
20090239813Analogs of Alpha Galactosyceramide and Uses thereof - There are disclosed compound of formula I, in which R09-24-2009
20090221516NOVEL GLYCOLIPID AND USE THEREOF - The present invention provide a compound represented by the following formula (1)09-03-2009
20090318372Method For Producing 2-O-Glyceryl-Alpha-D-Glucopyranoside - The present invention relates to a method for producing 2-O-glyceryl-α-D-glucopyranoside (αGG; FIG. 12-24-2009
20090143315Salix extract, its use and formulations containing it - The present invention relates to an extract of 06-04-2009
20080293643Crystalline Form I of 3,4'5-Trihydroxy-Stilbene-3-B-D Glucoside - The present invention relates to a novel crystalline form of a Compound 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. Crystalline form I of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside of the present invention has a stable crystalline morphology, a definite melting point and a good chemical stability. Such a novel form of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside possesses the properties required for the preparation of solid formulations and is easily tabletable and readily formable when formulated, which allows for substantial decrease in raw materials costs, more facile operations in production and easier control over quality in industrial drug production, and moreover, better convenience in storage.11-27-2008
20110237529Adenosine Analogs and Their Use - The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y09-29-2011
20090099102Ginkgolides in the Treatment and Prevention of Ovarian Cancer - The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in 04-16-2009
20120270815MODIFIED-GALACTOSYL CERAMIDES FOR STAINING AND STIMULATING NATURAL KILLER T CELLS - Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.10-25-2012
20130137648DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.05-30-2013
20100331268Nitrated Lipids and Methods of Making and Using Thereof - Described herein are nitrated lipids and methods of making and using the nitrated lipids.12-30-2010
20110009349METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT - One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.01-13-2011
20110021448Inhibitors for the Soluble Epoxide Hydrolase - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.01-27-2011
20110028410Use of Amygdalin Analogues for the Treatment of Psoriasis - The compounds of formula (1), wherein n is an integer from 0 to 4; R1 is a radical selected from the group consisting of H, CH02-03-2011
20100069312AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS FOR TREATING AUTOIMMUNE DISEASES - The invention provides prophylactic and therapeutic applications of select aminoalkyl glucosamine phosphate (AGP) compounds in autoimmune diseases.03-18-2010
20090215705Alpha 7 Nicotinic Receptor Selective Ligands - The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.08-27-2009
20090215704HEALTH-RELATED LIQUID COMPOSITIONS - There are disclosed liquid compositions comprising water, a fiber such as inulin, and a glycosaminoglycan that is selected from chondroitin sulfate, glucosamine, or a mixture thereof. The liquid compositions may further comprise at least one or more sweeteners, a source of calcium, at least one or more flavor additives, trehalose, at least one or more acids, sodium citrate, monopotassium phosphate, fruit juice, fruit juice concentrate, or the like, and any combination thereof. The liquid compositions may be suitable for use in health-related applications, among other applications.08-27-2009
20100062990NOVEL PSEUDOGLYCOLIPID AND USE THEREOF - The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof,03-11-2010
20100249047N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT - The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.09-30-2010
20110098239NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF - The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.04-28-2011
20110082097AMINO ACID COMPOSITION FOR IMPROVING GLUCOSE TOLERANCE - Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.04-07-2011
20120035118PHARMACEUTICAL COMBINATIONS - Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.02-09-2012
20120149655USE OF JASMONATE TO TREAT BLADDER DYSFUNCTION - A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.06-14-2012
20110257113Method for Inducing a Trif-Bias - The use of a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.10-20-2011
20110212907HEXADECASACCHARIDES WITH ANTITHROMBOTIC ACTIVITY, INCLUDING A COVALENT BOND AND AN AMINO CHAIN - The present invention relates to novel synthetic hexadecasaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.09-01-2011
20110212908TOPICAL COMPOSITIONS AND THE USE THEREOF - The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms on the skin of warm-blooded animals with coats.09-01-2011
20110178034PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH MONO- AND DISACCHARIDE-BASED COMPOUNDS - Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.07-21-2011
20110152207USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE - Disclosed are methods of treating vitamin D-sensitive diseases without inducing severe forms of hypercalcemia. The methods comprise administering biologically inert vitamin D prodrugs. The vitamin D prodrugs have a vitamin D-drug moiety and a pro moiety, wherein the pro moiety is selected from the group consisting of a glycone moiety and a sulfate moiety. The vitamin D prodrugs are activated by enzymes at target tissues or cells that cleave the pro moiety from the vitamin D-drug moiety, freeing the vitamin D-moiety from the pro moiety in the vicinity of the target tissues or cells. In some versions, the vitamin D-drug moiety is an active vitamin D drug that has direct therapeutic effects at target sites. In other versions, the vitamin D-drug moiety is an inactive vitamin D drug that regulates the production and/or turnover of an active vitamin D drug and, therefore, abundance of the active vitamin D drug at the target site. The methods of the invention prevent large, acute, systemic increases in the free form of the vitamin D-drug moiety that would otherwise lead to hypercalcemia. The methods can be used to treat hyperproliferative, autoimmune, or infectious diseases throughout the body, including the intestine. Compositions of the vitamin D prodrugs useful in the described methods are also disclosed.06-23-2011
20090143316COCRYSTAL OF C-GLYCOSIDE DERIVATIVE AND L-PROLINE - A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.06-04-2009
20110257112ISOLATED COMPOUNDS FROM PHALERIA MACROCARPA AS ANTI-CANCER AGENTS - The invention concerns compounds DLBS1425E2.2 and DLBS1425F1 isolated and identified from the extract of the plant 10-20-2011
20080312165Process for obtaining pure monosialoganglioside GM1 for medical use - A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.12-18-2008
20090118202COMPOSITIONS AND METHODS OF TREATING HYPERTENSION WITH TANNIN COMPLEXES - The present invention includes methods and compositions to ameliorate one or more symptom of hypertension through the inhibitor of an AT1 receptor by transcriptional down regulation of an angiotensin II type 1 receptor. The composition includes an effective amount of one or more tannic acids disposed in a pharmaceutically acceptable carrier.05-07-2009
20090048184Method for Producing a Drug Extract That Contains Hydroxystilbene - The invention relates to a method for producing drug extracts that contain hydroxystilbene from a vegetable drug and to the use of various agents for pharmaceutical and non-pharmaceutical purposes.02-19-2009
20110257111Hydroxyethlamino Sulfonamide Derivatives - This invention relates to novel hydroxyethylamino sulfonamides and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.10-20-2011
20110257109USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS - The present invention encompasses compositions and methods that activate P2Y receptors for the increased production of new synapses in the central nervous system. The formulations of the invention may be administered to a healthy subject or to a subject in need thereof to restore synapses.10-20-2011
20080214480Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae - The present invention is directed to methods of treating sickle cell disease and its sequelae, including vaso-occlusive crisis. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising an elective amount of a polyanionic polysaccharide, such as pentosan sulfate, sulodexide, or its pharmaceutically acceptable salts thereof. The methods of the present invention are useful in reducing the incidence, severity, or duration of SCD and its sequelae. The compound of the present method can also be used in conjunction with other therapeutic agents useful to treat sickle cell disease thus enhancing the therapeutic elect of reducing the required dosed to treat sickle cell disease.09-04-2008
20080255058Composition for Oral Cavity - The present invention relates to an oral care composition, which contains a compound represented by the formula (A):10-16-2008
20110257115METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS - The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.10-20-2011
20110257114CRYSTALLINE FORMS OF 1,6-BIS [3-(3-CARBOXYMETHYLPHENYL)-4-(2-ALPHA-D-MANNOPYRANOSYL-OXY)-PHENYL] HEXANE - The novel crystalline and polymorphic forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl]hexane have advantageous properties and can be used in pharmaceutical and dermatological compositions.10-20-2011
20100298245Pharmaceutical Composition for the Treatment of IL-8 mediated diseases - A compound of formula (I) can be used for the preparation of a pharmaceutical composition for the treatment, diagnosis or prophylaxis of Interleukin-8 related to viral infections.11-25-2010
20110136748NOVEL GLUCOPYRANOSE DERIVATIVES, PREPARATION THEREOF, AND BIOLOGICAL USES THEREOF - The invention relates to a novel ester, the 3,5-di-tertiobutyl-4-hydroxybenzoate of 3,4,5-trihydroxy-6-methoxytetrahydropyran-2-yl methyl defined by the following formula (I). The invention also relates to the method for preparing the compound of formula (I) and to the use of said compound (I) to prepare a drug for treating and/or preventing enveloped virus infections.06-09-2011
20090209475Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same - Sulfoquinovosylacyl propanediol compounds represented by formula (I):08-20-2009
20110257116BIOSURFACTANT-CONTAINING SKIN CARE COSMETIC AND SKIN ROUGHNESS-IMPROVING AGENT - The present invention relates to a cosmetic for skin roughness improvement/skin care containing a biosurfactant, particularly MEL-A, MEL-B or MEL-C.10-20-2011
20120178704PREVENTION AND TREATMENT OF COLON CANCER - Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.07-12-2012
20110178035METHOD FOR OBTAINING PURE MONOSIALOGANGLIOSIDE GM1 FOR MEDICAL USE - A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.07-21-2011
20090318373Receptor-type kinase modulators and methods of use - The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.12-24-2009
20120309699COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY - Compounds of general formula (I) for the treatment of inflammatory processes involved in numerous diseases such as intestinal inflammatory diseases. The invention moreover refers to compounds included within such general formula and to the procedure of the obtainment thereof.12-06-2012
20100190732USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY - This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity.07-29-2010
20100190731METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS - The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.07-29-2010
20100190729Composition for treating atopic dermatitis comprising hirsutanonol or oregonin as an active ingredient - The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13 associated with atopic dermatitis. In addition, hirsutanonol and oregonin increase MBD (mouse beta-defensin)-1, MBD-2 and MBD-3 expression and decrease COX-2 and iNOS expression in mouse animal model of atopic dermatitis. Hirsutanonol and oregonin as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis.07-29-2010
20110190226C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV - The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4′-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.08-04-2011
20110190227Antagonists of Prostaglandin D2 Receptors - Described herein are compounds that are antagonists of PGD08-04-2011
20110190225Topical method for prompt relief of severe ascites - A means is provided to make the capsules of cirrhotic or fibrotic livers relatively impermeable to liver tissue fluid or lymph in humans or other mammals suffering from severe chronic ascites or refractory ascites by application of collodion. The means will be useful to decrease the need for liver and combined liver and kidney transplantations08-04-2011
20100022462APPETITE SUPPRESSANT AND COLON CLEANSING COMPOSITION - The present invention provides low calorie, high potency, sugar free compositions and methods for making and using the same. In one embodiment, the composition of the present invention can be used to reduce daily food intake and facilitate detoxification and weight loss.01-28-2010
20110218160ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME - The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.09-08-2011
20100204163METABOLITES AND DERIVATIVES OF AMBRISENTAN - The invention relates to derivatives and metabolites of ambrisentan, including compounds of general Formula (I) or salts, hydrates, solvates, racemates, or optical isomers thereof, wherein R08-12-2010
20080293644GUAVA EXTRACT - The invention describes the preparation, isolation and use of an extract of guava fruit for the treatment of a disease or condition related with, caused by or mediated by dipeptidyl peptidase IV.11-27-2008
20080274985Pharmaceutical composition useful for the treatment of peptic ulcer diseases - The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant 11-06-2008
20110118198POLYSULFATED GLYCOSIDES AND SALTS THEREOF - The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.05-19-2011
20110118197PREVENTION OF HEPATIC ISCHEMIC REPERFUSION INJURY BY ADMINISTRATION OF SULFATIDES - Hepatic ischemic reperfusion injury is a major complication of liver transplantation, resectional hepatic surgeries, trauma surgery and shock. Disclosed herein are methods for the prevention and treatment of ischemia and reperfusion injury with the administration of sulfatides. Also disclosed herein are methods of preventing and treating hepatic reperfusion injury by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the injury.05-19-2011
20080318874Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes - A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I):12-25-2008
20110306569RHAMNOLIPID BIOSURFACTANT FROM PSEUDOMONAS AERUGINOSA STRAIN NY3 AND METHODS OF USE - The present disclosure relates to an isolated strain of 12-15-2011
20110306567POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY, INCLUDING A COVALENT BOND AND AN AMINO CHAIN - The present invention relates to novel synthetic polysaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.12-15-2011
20110306568COMPOSITION CONTAINING GLUCOSYLGLYCEROL - The invention relates to a composition containing 20 to 80% w/w of glucosyl-glycerol and 0.5 to 20% w/w of one or several mono- and/or disaccharides. Surprisingly, it has been found that an especially aqueous solution containing a high concentration of glucosylglycerol offers exceptionally high long-term stability. The composition has bactericidal and fungicidal effects.12-15-2011
20100279957PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS - Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with cancer are also provided. Kits including gene chips and instructions for predicting responsiveness and computer readable media comprising responsivity information are also provided.11-04-2010
20090012012Intratracheal administration of endothelin-suppressing agents for the treatment of respiratory disorders - The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of an agent that suppresses the activity of endothelin. Such agents may take the form of: 1) an endothelin-converting enzyme (ECE) inhibitor such as phosphoramidon, or 2) an endothelin receptor antagonist such as bosentan, tezosentan, sitaxsentan, atrasentan, darusentan, clazosentan, or BQ-123. Respiratory disorders include emphysema, asthma, bronchitis, bronchiectasis, pneumonia, adult respiratory distress syndrome, neonatal respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, persistent pulmonary hypertension of the newborn, and neoplasia. The treatment is intended for a variety of mammals, such as premature neonates to adult humans.01-08-2009
20090137496Use of Active Ingredients Containing Hydroxystilbene for Preventing and/or Treating Osteoporosis - The invention relates to the use of a combination of active ingredients containing hydroxystilbene, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of osteoporosis.05-28-2009
20100173856METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.07-08-2010
20120046238COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I):02-23-2012
20120046237COMPOSITIONS FOR PROTECTION AGAINST SUPERFICIAL VASODILATOR FLUSH SYNDROME, AND METHODS OF USE - Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.02-23-2012
20100035831ANTI-WRINKLE AGENT AND ADAM INHIBITOR - Disclosed is an anti-wrinkle agent for ameliorating a wrinkle (particularly a fine wrinkle) developed when the barrier function is decreased by dryness and the like. Also disclosed is an ADAM inhibitor. The anti-wrinkle agent or the ADAM inhibitor comprises an alkyl glucoside represented by the general formula: (1) [wherein R represents a linear or branched alkyl group having 1 to 18 carbon atoms] or a salt thereof.02-11-2010
20090215706C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula:08-27-2009
20120022009TANNATE DRY POWDER FORMULATIONS - Dry powder tannate compositions containing bioactive agents, tannic acid, dispersants, and viscosity modifying agents are disclosed. Specifically, the bioactive agents are antihistamines, decongestants, antitussives, and anticholinergics. The dry powder formulations can further include pharmaceutically acceptable excipients. The dry powder formulations exhibit increased stability for extended shelf life. Bioactive agent tannate salts remain suspended for at least two weeks following formation of the suspension in a pharmaceutically acceptable aqueous liquid.01-26-2012
20120022008Compounds and Method for Inhibiting the Activity of Gelatinase and Collagenase - Compounds extracted from 01-26-2012
20120058960FEEDBACK PRODRUG - Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.03-08-2012
20120065152PRODRUGS OF GUANFACINE - Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration are provided herein.03-15-2012
20120071426METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER - The present invention provides methods and compositions for treating lung cancer by cyclohexenone compounds.03-22-2012
20110105420AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION THEREOF - [Object] Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an α-amylase inhibitory activity, particularly a pharmaceutical composition for the treatment of diabetes.05-05-2011
20110105419PHARMACOLOGICAL ADJUVANTS BASED ON COORDINATION COMPOUNDS OF D-METALS - The invention relates to the use of small and ultra small quantities of bi- and oligo-nuclear forms of the coordination compounds of d-metals in the form of drugs or agents for enhancing the therapeutic efficiency of pharmacological substances.05-05-2011
20110105418PROCESS FOR PREPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF - Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.05-05-2011
20100093649Synthetic glycolipid analogues and derivatives for the treatment of pathologic disorders - The present invention describes compositions and methods for synthetic analogues and derivatives of β-glycolipids. These analogues and derivatives may be used for the treatment, amelioration or prevention of a pathological disorder. They may also be used for the modulation of the Th1/Th2 cell balance toward an anti-inflammatory or pro-inflammatory response, resulting in the treatment, amelioration or prevention of immune-related disorders.04-15-2010
20120129795ANTIVIRAL COMPOUNDS - Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.05-24-2012
20100210572HYDROLYSATE OF CROCIN - The present invention relates to a composition derived from the hydrolysate of plant containing crocin or the derivatives thereof. The composition includes a significant amount of crocetin monoester. The present invention also provides a method to hydrolyze crocin existing in a plant extract, and further relates to the use.08-19-2010
20120172321HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula:07-05-2012
20120214754FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R08-23-2012
20100048493METHOD OF ADMINISTERING ORAL FLORA-IMPROVING AGENT, ANTIBACTERIAL AGENT AND GROWTH PROMOTER - It is intended to provide an oral flora-improving agent capable of forming a favorable flora in the oral cavity and a food or a drink for improving the oral flora. An oral flora-improving agent containing as an active ingredient a ganglioside and a food, a drink, or a feed for improving the oral flora containing the ganglioside exhibit an antibacterial effect on harmful bacteria in the oral cavity, which are undesirable from the viewpoint of decay and diseases such as periodontal disease, and a growth-improving effect on useful bacteria to be preserved in the oral cavity. Further, the ganglioside is efficaciously used as an active ingredient in an antibacterial agent or an antibacterial drink, food, or feed, a growth promoter, or a food, a drink, or a feed for promoting growth.02-25-2010
20100048492COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH TNF AND/OR IL-12 OVEREXPRESSION - The present invention relates to a pharmaceutical composition comprising at least one compound of formula (I):02-25-2010
20100279959Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors - A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.11-04-2010
20100279958COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION - Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.11-04-2010
20120178705METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF - Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.07-12-2012
20120178706METHOD FOR PREPARING A CENTELLA ASIATICA EXTRACT RICH IN MADECASSOSIDE AND IN TERMINOLOSIDE - The invention concerns an extract of 07-12-2012
20100273725Novel compounds useful in therapeutic and cosmetic methods - The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties in the treatment of certain diseases and lack the undesired damages to healthy skin entailed by prior art compounds. ALA (5-aminolevulinic acid)-esters of body-owned, natural compound such as aminoacids, steroids, carbohydrades, alcohols are preferred, examples of photosensitizers of the present invention. The compounds of the present invention are used in the treatment of skin diseases such as psoriasis, sebaceous glands related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer and precancer, as well as in cosmetic hair removal.10-28-2010
20120122806METHOD OF LOWERING GLYCEMIC INDEX OF FOODS - A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogues and derivatives.05-17-2012
20090069253WHITENING COSMETIC COMPOSITION CONTAINING ARBUTIN NANOPARTICLES - The present invention provides a whitening cosmetic composition containing arbutin at a high concentration, whereby an improved whitening effect can be attained. In the arbutin-containing whitening cosmetic composition, arbutin is in the form of nanoparticles obtained through a nanoparticle-forming treatment of an aqueous arbutin dispersion. The composition preferably contains arbutin nanoparticles having a particle size of 10 to 150 nm in an amount of 1 to 15 wt. %.03-12-2009
20120220544Ganglioside Transmucosal Formulations - A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.08-30-2012
20120220543Treatment of Glaucoma and Other Retinopathies with Gangliosides - A method of treating or preventing a retinopathy such as glaucoma in a human patient in need thereof comprising administering one or more gangliosides to the patient.08-30-2012
20100004186Antithrombotic Dual Inhibitors Comprising A Biotin Residue - The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (1), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO01-07-2010
20120083459USE OF GANGLIOSIDE TO DECREASE PROPAGATION OF MALIGNANT PROSTATE CELLS - Uses of exogenous ganglioside to inhibit the propagation of prostate cancer cells are provided. Gangliosides regulate many cellular processes including cell death. The present disclosure assesses the role of ganglioside in prostate cell growth. Malignant prostate (PC-3) and control (RWPE-1) cells can be cultured with or without ganglioside treatment. Cells can be assayed for differences in cell growth. Supplementation with ganglioside (GD3) can decrease growth of PC-3 cells by 30% compared to controls (p<0.01). Ganglioside can have therapeutic benefit in prostate cancer as demonstrated by decreased growth of malignant PC-3 cells.04-05-2012
20120190634LIPOTEICHOIC ACID-DERIVED GLYCOLIPIDS, AND COMPOSITIONS COMPRISING SAME - A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used to prevent and treat inflammatory diseases, and the LTA-derived glycolipid can be also used as the vaccine adjuvant.07-26-2012
20100190730APPLICATION OF 5-METHYL-1,3-BENZENEDIOL OR DERIVATIVES THEREOF IN THE PREPARATION OF MEDICINES AND FUNCTIONAL FOODS FOR TREATMENT OR PREVENTION OF DEPRESSION - The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.07-29-2010
20110124587Pure Rebaudioside A - The invention provides a high throughput, high purity, high yield system and method of isolating and purifying rebaudioside A (“Reb A”), with acceptable water solubility for all commercial uses, from commercially available 05-26-2011
20120264703Methods And Compositions For The Treatment Of Anxiety Disorders, Including Post Traumatic Stress Disorder (PTSD) And Related Central Nervous System (CNS) Disorders. - The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using α and β blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.10-18-2012
20120264702Synthesis And Use Of Glycoside Derivatives of Propofol - The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug propofol analogs. This invention relates to a method for the production of a broad group of glycosylated propofol carbohydrate derivatives.10-18-2012
20080300196MONOSACCHARIDE DERIVATIVES - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.12-04-2008
20120238512ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE - The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO09-20-2012
20100204166POLYACETYLENIC COMPOUNDS FOR STIMULATING INSULIN GENE EXRESSION, PRODUCTION AND SECRETION - This invention relates to a method of treating type II diabetes with a polyacetylenic compound of the following formula:08-12-2010
20100204165Pesticidal Compositions - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.08-12-2010
20100204164PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.08-12-2010
20110046078METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH SIGLEC-8 - The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well as other animals, through the administration of one or more novel, carbohydrate-based compounds.02-24-2011
20120322751 USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS - This invention is related to the use of one or more rhamnolipids based on structure Formula 1 where the composition of the mixture is useful in the treatment of combination radiation illnesses and regeneration of cells and/or tissues by different application ways of any desirable mentioned rhamnolipids. These rhamnolipid composition mixture are very suitable in the treatment of combination radiation injuries and illnesses and for the regeneration of human and animal cells and tissues after nuclear catastrophes; comprising two or more injuries/illnesses and for cell and tissue regenerations which include radiation damages combined with burns, mechanical injuries, infections of digestive system, infections of lungs, neutropenia, sepsis, atherosclerosis, depression, schizophrenia, atopic eczema and other illnesses in connection with radiation injuries.12-20-2012
20120322750SOLUBILIZATION AGENT FOR SOLUBILIZING POLYPHENOLS, FLAVONOIDS AND/OR DITERPENOID GLUCOSIDES - Described is a solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides in aqueous liquids, wherein the solubilization agent consists of a mixture of:12-20-2012
20110237531METHOD FOR PRODUCING SOPHOROSE LIPID - The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the lactonic sophorose lipids in a solid form. Further, the present invention enables production of high purity acidic sophorose lipids by hydrolyzing high purity lactonic sophorose lipids produced by the above method. The present invention also provides lactonic sophorose lipids that possess strong antibacterial and antifungal activities, and an antibacterial and/or antifungal agent containing the sophorose lipids.09-29-2011
20120277172CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION - The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.11-01-2012
20120329737HYBRID MOLECULES MADE OF LIPIDS AND LIPID-ANALOGOUS COMPOUNDS AND USE THEREOF AS PHARMACEUTICAL OR COSMETIC PREPARATION - The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation.12-27-2012
20120329736Treatment for gastrointestinal disorders using a selective, site-activated binding system - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme.12-27-2012
20130012461COMPOSITION FOR PREVENTION OF INFLUENZA VIRAL INFECTION COMPRISING TANNIC ACID, AIR FILTER COMPRISING THE SAME AND AIR CLEANING DEVICE COMPRISING THE FILTER - Disclosed are a composition for the prophylaxis of influenza viral infection comprising tannic acid, an air filter coated with the same, and an air cleaner comprising the air filter. Having high inhibitory activity against influenza virus, the composition comprising tannic acid can be applied to the prevention of influenza viral infection. Also, the filter coated with the composition can remove influenza virus from the air so that it can be employed in an air cleaner for the prophylaxis of influenza viral infection.01-10-2013
20130018006Atheroscleroclastic Bioceutical Formulations - A group of compounds formed from phosphorylated monosaccharides and/or phosphorylated oligosaccharides esterified with physiologic methyl donors consisting of choline, and methyl donors chosen from a group consisting of esteried with a substance chosen from the group consisting of methylene choline and all their derivatives and metabolites thereof.01-17-2013
20110160151Novel Acetates of 2-Deoxy Monosaccharides with Anticancer Activity - Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.06-30-2011
20080249032Derivatives of Arylsulfonamido-Substituted Hydroxamic Acid as Matrix Metalloproteinases Inhibitors - Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin.10-09-2008
20120252744Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease - A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure of formula (I).10-04-2012
20130130997C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF - C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.05-23-2013
20130143828GLYCOLIPID FOR TREATMENT OF ISCHEMIA REPERFUSION INJURY - The invention relates to a high molecular weight glycolipid characterized by the presence of rhamnose which has anti-inflammatory activity, particularly in inflammation triggered by ischemia and reperfusion. A further aspect of the invention is a process for preparation of said glycolipid from Cyanobacteria.06-06-2013
20080207533Pharmaceutical Compositions - A pharmaceutical composition and granulates, prepared by a wet granulation process. The pharmaceutical composition and granulates contain a therapeutic compound, e.g., the 3′-L-valine ester of β-D-2′-C-methyl ribofuranosyl cytidine and its salts, esters, prodrugs or derivatives.08-28-2008
20110224156Propionic Acids, Propionic Acid Esters, and Related Compounds - The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).09-15-2011
20110224155MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH - The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having Formula (I), its subgenus, and specific compounds. Furthermore, the present invention includes ingestible compositions comprising the modifiers of chemosensory receptors and their ligands and methods of using the modifiers of chemosensory receptors and their ligands to enhance the sweet taste of an ingestible composition or treat a condition associated with a chemosensory receptor. In addition, the present invention include processes for preparing the modifiers of chemosensory receptors and their ligands.09-15-2011
20110275578TREATMENT OF NEPHROLITHIASIS AND UROLITHIASIS USING 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE (PGG) - The treatment of nephrolithiasis or urolithiasis by methods that include administration of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) or a salt or derivative thereof, or a pharmaceutically acceptable composition comprising the same are provided herein.11-10-2011
20110275577METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS - The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.11-10-2011
20110237530ANTI-XDR-TB DRUG, ANTI-MDR-TB DRUG, AND COMBINATION ANTI-TUBERCULOSIS DRUG - A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:09-29-2011
20110257110Composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition - A composition and use of a composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, e.g. fish oil. The composition may also comprise a rose hip concentrate. The composition is used to treat inflammatory diseases, e.g. joint diseases such as osteoarthritis, or joint pain and stiffness. By administering the composition on a daily basis, a significant reduction in joint pain and stiffness of the affected joints is achieved, which allows individuals suffering from especially joint diseases to resume daily activities.10-20-2011
20110257108SYNTHESIS AND ACTIVITY OF LACTOSE ESTERS - This disclosure provides for a novel lactose monolaurate (LML) with the structure10-20-2011
20100317604FORSYTHIASIDE INJECTION PREPARATION AND PREPARATIVE METHOD THEREOF - The present invention discloses a Forsythiaside injection preparation and preparative method thereof. This injection preparation is prepared by Forsythiaside and pharmaceutical adjuvant.12-16-2010
20100317603Treatment of Cancer and Inflammatory Disorder - Disclosed are extracts, compositions, and methods for treating cancer and inflammatory disorders. Also disclosed are methods for preparing extracts or compounds for treating the disorders.12-16-2010
201202832019-SUBSTITUTED MINOCYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.11-08-2012
20120283200PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING CHRONIC HEART DISEASE - The present invention provides a pharmaceutical composition for preventing or treating a chronic heart disease, comprising a compound of a formula (I):11-08-2012
20120283199NEUROPROTECTIVE GANGLIOSIDE COMPOSITIONS FOR USE IN TREATING OR DIAGNOSING HUNTINGTON'S DISEASE - Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a polyglutamine stretch in the protein huntingtin (Htt). HD neurons are dysfunctional at multiple levels and have increased susceptibility to stress and apoptotic stimuli. As described therein there is provided compound(s), composition(s), methods and/or kits for the treatment and/or diagnosis of Huntington's disease.11-08-2012
20100298246Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same - Sulfoquinovosylacyl propanediol compounds represented by formula (I):11-25-2010
20130190256Curcumin Derivatives - The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.07-25-2013
20130190257Methods of Ganglioside Production - The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.07-25-2013
201200289156"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds.02-02-2012
20120035119Extracts and Compounds from Ficus Benghalensis for Increasing Hair Growth and Decreasing Hair Loss - This application discloses natural product extracts and compounds from an aerial root of a 02-09-2012
20130203688SUGAR PLANT DERIVED BY-PRODUCTS AND METHODS OF PRODUCTION THEREOF - The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product.08-08-2013
20130203689CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.08-08-2013
20120077762COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEART FAILURE - Disclosed herein are compounds, extracts, and active fractions of the plant 03-29-2012
20120094943ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS - The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.04-19-2012

Patent applications in class O-glycoside

Patent applications in all subclasses O-glycoside